skip to main content

Persistent storage LUTS/overactive bladder symptoms after alpha-blocker treatment for LUTS secondary to benign

Instant feedback + full explanation. One question, done properly.

ModerateLUTSPersistent storage LUTS/overactive bladder symptoms after alpha-blocker treatment for LUTS secondary to benign prostatic enlargementMSRA

A 67-year-old man is reviewed in a community urology clinic 8 weeks after starting tamsulosin MR 400 micrograms once daily for moderate-to-severe LUTS. His weak stream, hesitancy and intermittency have improved substantially. However, he remains troubled by urinary urgency, daytime frequency and occasional urge urinary incontinence. A 3-day frequency-volume chart shows frequent small-volume voids and no nocturnal polyuria. Urine culture is negative. Uroflowmetry shows a maximum flow rate of 16 mL/second and post-void residual volume is 60 mL. Digital rectal examination shows a smooth prostate estimated at 28 g. PSA before treatment was 0.9 micrograms/L. He has no glaucoma, cognitive impairment, constipation, recurrent UTI or symptoms of incomplete emptying. What is the most appropriate next pharmacological management?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Continue tamsulosin and add an anticholinergic medicine, with review in 4–6 weeks

This man has persistent storage LUTS consistent with overactive bladder despite a satisfactory response of his voiding symptoms to tamsulosin. His low post-void residual volume, adequate flow rate and absence of ongoing emptying symptoms make clinically significant retention unlikely. NICE advises considering an anticholinergic in addition to an alpha blocker when storage symptoms persist after alpha-blocker monotherapy. Anticholinergic treatment should then be reviewed after 4–6 weeks until symptoms are stable. A 5-alpha reductase inhibitor is not indicated: his prostate is below 30 g and PSA is below 1.4 ng/mL, so he is not in the group at higher risk of progression for whom finasteride is recommended. Desmopressin is used for nocturnal polyuria after other causes have been excluded; his bladder diary instead demonstrates reduced functional bladder capacity with frequent small-volume voiding. Mirabegron is an option when anticholinergics are unsuitable, ineffective or not tolerated, but there is no such contraindication here, and stopping a beneficial alpha blocker would risk recurrence of voiding symptoms. Waiting without adjustment is inappropriate because he has already had an adequate alpha-blocker trial and remains significantly symptomatic.

Reference: NICE CG97: Lower urinary tract symptoms in men: management — recommendations (2010; current NICE page checked 15 August 2026) — https://www.nice.org.uk/guidance/cg97/chapter/recommendations NICE CG97: Lower urinary tract symptoms in men: management — recommendations (2010; current NICE page checked 15 August 2026) — https://www.nice.org.uk/guidance/cg97/chapter/recommendations NICE CG97: Lower urinary tract symptoms in men: management — recommendations (2010; current NICE page checked 15 August 2026) — https://www.nice.org.uk/guidance/cg97/chapter/recommendations